Systemic therapies for endometrial carcinoma

Brian Slomovitz, Karen H. Lu

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Because of the hematogenous and lymphatic spread of endometrial cancer (EC), patients with recurrent or advanced disease often present with tumor outside of the pelvis. Systemic therapy, therefore, plays an important role in the management of these patients. Both hormonal and cytotoxic agents have activity in patients with advanced or recurrent EC. However, neither of these types of therapies is considered curative in patients with distant, metastatic disease.

Original languageEnglish (US)
Title of host publicationCancer of the Uterus
PublisherCRC Press
Pages407-434
Number of pages28
ISBN (Electronic)9780849377884
ISBN (Print)0824754158, 9780824754150
StatePublished - Jan 1 2004
Externally publishedYes

Fingerprint

Endometrial Neoplasms
Play Therapy
Cytotoxins
Therapeutics
Pelvis
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Slomovitz, B., & Lu, K. H. (2004). Systemic therapies for endometrial carcinoma. In Cancer of the Uterus (pp. 407-434). CRC Press.

Systemic therapies for endometrial carcinoma. / Slomovitz, Brian; Lu, Karen H.

Cancer of the Uterus. CRC Press, 2004. p. 407-434.

Research output: Chapter in Book/Report/Conference proceedingChapter

Slomovitz, B & Lu, KH 2004, Systemic therapies for endometrial carcinoma. in Cancer of the Uterus. CRC Press, pp. 407-434.
Slomovitz B, Lu KH. Systemic therapies for endometrial carcinoma. In Cancer of the Uterus. CRC Press. 2004. p. 407-434
Slomovitz, Brian ; Lu, Karen H. / Systemic therapies for endometrial carcinoma. Cancer of the Uterus. CRC Press, 2004. pp. 407-434
@inbook{8416eb442bc24a0783af9f6f1352f103,
title = "Systemic therapies for endometrial carcinoma",
abstract = "Because of the hematogenous and lymphatic spread of endometrial cancer (EC), patients with recurrent or advanced disease often present with tumor outside of the pelvis. Systemic therapy, therefore, plays an important role in the management of these patients. Both hormonal and cytotoxic agents have activity in patients with advanced or recurrent EC. However, neither of these types of therapies is considered curative in patients with distant, metastatic disease.",
author = "Brian Slomovitz and Lu, {Karen H.}",
year = "2004",
month = "1",
day = "1",
language = "English (US)",
isbn = "0824754158",
pages = "407--434",
booktitle = "Cancer of the Uterus",
publisher = "CRC Press",

}

TY - CHAP

T1 - Systemic therapies for endometrial carcinoma

AU - Slomovitz, Brian

AU - Lu, Karen H.

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Because of the hematogenous and lymphatic spread of endometrial cancer (EC), patients with recurrent or advanced disease often present with tumor outside of the pelvis. Systemic therapy, therefore, plays an important role in the management of these patients. Both hormonal and cytotoxic agents have activity in patients with advanced or recurrent EC. However, neither of these types of therapies is considered curative in patients with distant, metastatic disease.

AB - Because of the hematogenous and lymphatic spread of endometrial cancer (EC), patients with recurrent or advanced disease often present with tumor outside of the pelvis. Systemic therapy, therefore, plays an important role in the management of these patients. Both hormonal and cytotoxic agents have activity in patients with advanced or recurrent EC. However, neither of these types of therapies is considered curative in patients with distant, metastatic disease.

UR - http://www.scopus.com/inward/record.url?scp=85056955635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056955635&partnerID=8YFLogxK

M3 - Chapter

SN - 0824754158

SN - 9780824754150

SP - 407

EP - 434

BT - Cancer of the Uterus

PB - CRC Press

ER -